Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maravai LifeSciences Holdings, Inc.

2.75
+0.05001.85%
Post-market: 2.750.00000.00%18:41 EDT
Volume:1.17M
Turnover:3.20M
Market Cap:702.24M
PE:-2.04
High:2.80
Open:2.72
Low:2.66
Close:2.70
52wk High:8.99
52wk Low:1.67
Shares:255.36M
Float Shares:144.68M
Volume Ratio:0.68
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3483
EPS(LYR):-1.0503
ROE:-54.84%
ROA:-5.89%
PB:2.64
PE(LYR):-2.62

Loading ...

Company Profile

Company Name:
Maravai LifeSciences Holdings, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
560
Office Location:
10770 Wateridge Circle,Suite 200,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Directors

Name
Position
Bernd Brust
Director and Chief Executive Officer
Robert Andrew Eckert
Chairman of the Board
Gregory T. Lucier
Independent Director
Jessica Hopfield
Independent Director
John A. DeFord
Independent Director
Murali K. Prahalad
Independent Director
Susannah Gray
Independent Director
Benjamin Daverman
Director
Constantine Mihas
Director
Luke Marker
Director
Sean Cunningham
Director

Shareholders

Name
Position
Bernd Brust
Director and Chief Executive Officer
Rajesh J. Asarpota
Chief Financial Officer
Christine Dolan
Executive Vice President and General Manager, Cygnus Technologies
Kevin Herde
Principal Accounting Officer
Kurt Oreshack
General Counsel and Secretary